Esperion Therapeutics (ESPR) Change in Receivables (2020 - 2026)

Esperion Therapeutics' Change in Receivables history runs 7 years deep, the most recent figure standing at -$7.8 million for Q1 2026.

• Quarterly Change in Receivables fell 780.38% year-over-year to -$7.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $51.1 million (up 91.36% YoY) and the FY2025 annual result came in at $60.0 million, up 89.74% from the prior year.
• Change in Receivables was -$7.8 million for Q1 2026 at Esperion Therapeutics, down from $21.2 million in the prior quarter.
• Across five years, Change in Receivables topped out at $26.5 million in Q2 2025 and bottomed at -$7.8 million in Q1 2026.
• A 5-year average of $6.4 million and a median of $4.4 million in 2023 frame the typical range for Change in Receivables.
• Annual changes were most pronounced in 2022 — Change in Receivables surged 2631.25% — and 2026, when it sank 780.38%.
• Esperion Therapeutics' Change in Receivables stood at $2.2 million in 2022, then surged by 162.1% to $5.9 million in 2023, then surged by 109.81% to $12.3 million in 2024, then soared by 72.19% to $21.2 million in 2025, then sank by 136.95% to -$7.8 million in 2026.
• Business Quant data shows ESPR's Change in Receivables at -$7.8 million in Q1 2026, $21.2 million in Q4 2025, and $11.2 million in Q3 2025.